Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by gregoooon Nov 10, 2010 11:59am

434 Views

Post# 17686845

RE: RE: RE: We know for sure that testing is now d

from CNE's NR

The rig will be mobilized to the Rancho Hermoso 8 ("RH 8") well which is anticipated to spud the first week of November. The RH 8 well will target the Los Cuervos - Barco and Guadalupe reservoirs at a location approximately 1,500 ft to the southwest of the Rancho Hermoso 5 ("RH 5") well. Meanwhile, the Corporation has contracted the Saxon 132 drilling rig which is being mobilized to the Rancho Hermoso 9 ("RH 9) location to commence drilling in mid November. The RH 9 well will target the deeper Ubaque reservoir at a location approximately 3,000 ft to the southwest of the RH 5 well.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity